Pharmacokinetics of S-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4- nitro-3-trifluoromethyl-phenyl)-propionamide in rats, a non-steroidal selective androgen receptor modulator

Xenobiotica

Volumn 34, Issue 3, 2004, Pages 273-280

  Kearbey, J D ^a   Wu, D ^a   Gao, W ^a   Miller, D D ^b   Dalton, J T ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; BENZENE DERIVATIVE; PROPIONAMIDE DERIVATIVE; S 3 (4 ACETYLAMINOPHENOXY) 2 HYDROXY 2 METHYL N (4 NITRO 3 TRIFLUOROMETHYLPHENYL)PROPIONAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; FEEDING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NONHUMAN; RANDOMIZATION; RAT; RAT STRAIN;

ACETAMIDES; ADMINISTRATION, ORAL; AMINOPHENOLS; ANIMALS; BIOLOGICAL AVAILABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; INFUSIONS, INTRA-ARTERIAL; MALE; METABOLIC CLEARANCE RATE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ANDROGEN; TESTOSTERONE CONGENERS;

ANIMALIA;

EID: 1842627842     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/0049825041008962     Document Type: Article

References (15)

1. BHASIN, S., and BREMNER, W. J., 1997, Clinical review 85: Emerging issues in androgen replacement therapy. Journal of Clinical Endocrinology and Metabolism, 82, 3-8.
2. BOYLE, G. W., MCKILLOP, D., PHILLIPS, P. J., HARDING, J. R., PICKFORD, R., and MCCORMICK, A. D., 1993, Metabolism of casodex in laboratory animals. Xenobiotica, 23, 781-798.
3. DALTON, J. T., MUKHERJEE, A., ZHU, Z., KIRKOVSKY, L., and MILLER, D. D., 1998, Discovery of nonsteroidal androgens. Biochemical and Biophysical Research Communications, 244, 1-4.
4. DAVIES, B., and MORRIS, T., 1993, Physiological parameters in laboratory animals and humans. Pharmaceutical Research, 10, 1093-1095.
5. HANDELSMAN, D. J., CONWAY, A. J., and BOYLAN, L. M., 1990, Pharmacokinetics and pharmacodynamics of testosterone pellets in man. Journal of Clinical Endocrinology and Metabolism, 71, 216-222.
6. HEYWOOD, R., CHESTERMAN, H., BALL, S. A., and WADSWORTH, P. F., 1977, Toxicity of methyl testosterone in the beagle dog. Toxicology, 7, 357-365.
7. ISHAK, K. G., and ZIMMERMAN, H. J., 1987, Hepatotoxic effects of the anabolic/androgenic steroids. Seminars in Liver Disease, 7, 230-236.
8. KEARBEY, J. D., GAO, W., MILLER, D. D., and DALTON, J. T., 2003, Selective androgen receptor modulators inhibit bone resorption in rats. AAPS Pharm Sci, 5, Abstract R6167.
9. MARHEFKA, C. A., GAO, W., CHUNG, K., KIM, J., HE, Y., YIN, D., BOHL, C., DALTON, J. T., and MILLER, D. D., 2003, Design, synthesis, and biological characterization of metabolically stable selective androgen receptor modulators. Journal of Medicinal Chemistry (in press).
10. NEGRO-VILAR, A., 1999, Selective androgen receptor modulators (SARMs): A novel approach to androgen therapy for the new millennium. Journal of Clinical Endocrinology and Metabolism, 84, 3459-3462.
11. VELAZQUEZ, E., and BELLABARBA ARATA, G., 1998, Testosterone replacement therapy. Archives of Andrology, 41(2), 79-90.
12. WILSON, J. D., 1996, Androgens. In J. G. Hardman, L. E. Limbird, P. B. Molinoff, R. W. Ruddon and A. G. Gilman (eds), The Pharmacological Basis of Therapeutics (New York: McGraw-Hill), pp. 1441-1458.
13. WILSON, J. D., AIMAN, J., and MACDONALD, P. C., 1980, The pathogenesis of gynecomastia. Advances in Internal Medicine, 25, 1-32.
14. WU, F. C., 1992, Testicular steroidogenesis and androgen use and abuse. Baillieres Clinical Endocrinology and Metabolism, 6, 373-403.
15. YIN, D., GAO, W., KEARBEY, J. D., XU, H., CHUNG, K., HE, Y., MARHEFKA, C. A., VEVERKA, K. A., MILLER, D. D., and DALTON, J. T., 2003, Pharmacodynamics of selective androgen receptor modulators. Journal of Pharmacology and Experimental Therapeutics, 304, 1334-1340.